Home » Catalent Establishes New Drug Delivery Institute
Catalent Establishes New Drug Delivery Institute
Catalent
PharmaManufacturing.com
10/18/2012
Catalent Pharma Solutions announced the launch of its Catalent Applied Drug Delivery Institute at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Chicago, IL.
The Catalent Applied Drug Delivery Institute aspires to promote innovation, knowledge-sharing, and collaboration between industry leaders, academic experts, customers and regulators to enhance understanding of available, emerging, and future drug delivery technologies and improve patient care.
“The mission of the Catalent Applied Drug Delivery Institute is to bring better treatments to market by advancing the development and adoption of applied drug delivery technologies,” stated Kurt Nielsen, Ph.D., senior vice president of research and development. “By harnessing the knowledge of some of the world’s leading experts in drug development, delivery and formulation, the Institute will cultivate leadership and excellence in drug development through education, training, and innovation.”
As part of its mission, the Catalent Applied Drug Delivery Institute will serve as a link between industry and academia by providing guidance, counsel, and resources on major issues pertaining to drug development, delivery, and formulation. The Institute will develop programs that facilitate mutually beneficial collaborations, increase communication, and shed light on regulatory issues affecting drug developers and researchers. It also will pursue a multi-tiered approach of seed funding, strategic counsel, and educational programs to advance the adoption of emerging technologies.
“Today is an exciting day for Catalent Pharma Solutions and the Catalent Applied Drug Delivery Institute, as well as for everyone working in the areas of drug delivery and development,” said Rao Tatapudy, Vice President of Scientific Affairs. “In launching the Institute at AAPS, we hope to start an informative and productive dialog between industry and academic experts that will spur innovation at the benchtop and in the marketplace. We look forward to a continuous series of successful collaborations as the Institute’s activities unfold.”
There will be a series of Institute-led initiatives designed to enhance understanding of drug delivery and inspire the next generation of science leaders. These initiatives, which will target both industry and academic audiences, will include:
· Applied Drug Delivery Events and Training Programs for Industry
· Innovation and Research Collaborations with Universities and Technology Companies
· Catalent Applied Drug Delivery Institute Scientific Journal
· Science Leaders of Tomorrow University Partnership Program
· Student Drug Delivery Guide
· Annual Drug Delivery Landscape Technology Survey
· Scientific Communications
For more information about the Catalent Applied Drug Delivery Institute, visit www.drugdeliveryinstitute.com.
More News:
-
05/22/2013
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
-
05/22/2013
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
-
05/22/2013
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
-
05/21/2013
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
-
05/21/2013
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
-
05/21/2013
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
-
05/17/2013
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
-
05/16/2013
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
-
05/16/2013
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
-
05/15/2013
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
- All news »
- Popular Articles
- Newest Articles
- Popular Downloads
Get Connected Now!
- Featured White Papers

Print page